Nuveen Asset Management LLC Reduces Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Nuveen Asset Management LLC cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 384,486 shares of the company's stock after selling 27,529 shares during the period. Nuveen Asset Management LLC owned about 0.47% of IDEXX Laboratories worth $158,962,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. United Capital Financial Advisors LLC increased its position in shares of IDEXX Laboratories by 0.9% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after acquiring an additional 22 shares in the last quarter. Cranbrook Wealth Management LLC increased its holdings in IDEXX Laboratories by 7.0% in the 4th quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after acquiring an additional 25 shares during the last quarter. Gabelli Funds LLC lifted its position in shares of IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after acquiring an additional 25 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after buying an additional 26 shares in the last quarter. Finally, Summit Trail Advisors LLC grew its stake in IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after acquiring an additional 26 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 0.9%

Shares of NASDAQ:IDXX traded down $4.52 on Tuesday, reaching $517.16. The company had a trading volume of 601,913 shares, compared to its average volume of 810,178. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $41.59 billion, a PE ratio of 48.47, a PEG ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $530.60. The firm's 50 day simple moving average is $433.47 and its 200-day simple moving average is $432.18.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.71 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on IDXX shares. Bank of America lifted their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Morgan Stanley increased their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Barclays boosted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Finally, Piper Sandler lifted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus target price of $536.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.